Questions // Direct answers
Thymosin Alpha-1: Frequently Asked Questions
Plain, cited answers to the questions people actually ask about this thymic immune peptide.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid, N-terminally acetylated thymic polypeptide first isolated from calf thymus (as part of thymosin fraction 5). Goldstein and colleagues purified it and determined its complete amino-acid sequence in 1977 [1]. It is an immune-modulating peptide; the synthetic, sequence-identical drug version is called thymalfasin.
Where does thymosin alpha 1 come from in the body?
It is endogenous — your body makes it. It is cut from a larger 113-amino-acid parent protein, prothymosin alpha, and a biochemical study confirmed that cleaving recombinant prothymosin alpha yields mature, acetylated Thymosin Alpha-1 identical to the synthetic form [11]. It was first isolated from calf thymus, and circulating levels decline with age [1].
What is thymalfasin?
Thymalfasin is the International Nonproprietary Name (the official generic name) for the synthetic version of Thymosin Alpha-1 used in trials and marketed abroad. It is an exact copy of the natural 28-amino-acid sequence, so research on it describes the same molecule [4]. It is approved in roughly 35 countries and not approved in the United States.
What does thymosin alpha 1 do?
It modulates the immune system. It signals through TLR2 and TLR9 on dendritic cells to drive their maturation and a Th1 (cell-killing) T-cell response, while also activating the IDO pathway to generate regulatory T-cells [5]. The net effect is a dual one: restoring worn-down immunity while damping overreaction. It is not anabolic and does not build muscle.
What is thymosin alpha 1 used for?
Abroad it is used mainly for chronic hepatitis B and as an immune adjuvant. A cancer reappraisal also positions it as an immunostimulatory adjuvant alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, acting through dendritic cells and the adaptive immune response [7]. In the US it has no marketing approval and exists only in investigational and compounding contexts.
Is thymosin alpha 1 FDA-approved?
No. Thymosin Alpha-1 (thymalfasin) is not FDA-approved for marketing in the United States. It is approved as a drug in roughly 35 other countries, but US availability is limited to investigational and compounding settings. The FDA has evaluated related bulk substances for compounding and has not endorsed them [4].
What is TA1 peptide?
'TA1 peptide' (also written Tα1) is just another name for Thymosin Alpha-1 — the same 28-amino-acid acetylated thymic immune peptide isolated and sequenced by Goldstein and colleagues in 1977 [1]. The 'TA1' shorthand and the 'thymalfasin' drug name both refer to this one molecule, not a different compound.
Who should not take thymosin alpha 1?
This digest gives no personal guidance, but the literature flags theoretical cautions: people with established autoimmune disease (because it stimulates effector immunity) [16], solid-organ transplant recipients (who are deliberately immunosuppressed) [5], and anyone pregnant or breastfeeding, since dedicated safety data are absent [4]. Those are theoretical concerns, not findings, and any decision belongs with a clinician.
Is TB-500 the same as thymosin alpha 1?
No. TB-500 is a form of thymosin beta-4, a 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Thymosin Alpha-1 is a 28-amino-acid acetylated immune-modulating peptide [1]. Different sequence, size, mechanism, and use — they share only a family name, and thymosin beta-4 is the one flagged in anti-doping contexts.
How long should you take thymosin alpha 1?
Trial durations vary by setting and are research data, not advice. A comprehensive review describes multiple-dose regimens over five to seven days for acute settings, the 1.6 mg twice-weekly chronic hepatitis regimen, and, in one cancer study, weekly injection for up to 12 months [4]. There is no general-purpose duration; it depends entirely on the studied indication.
How long does it take for thymosin alpha 1 to work?
Pharmacologically it acts fast: after a subcutaneous dose in volunteers it peaks in about one to two hours, with an elimination half-life near two hours [4]. Any immune effect, however, is biochemical and builds over a course rather than producing an immediate sensation, which is why many users report not feeling anything. Onset of clinical benefit is study- and indication-specific.
What is the dosing protocol for thymosin alpha 1?
Reported as research data only: a comprehensive review puts single subcutaneous doses at 0.8 to 6.4 mg and multiple-dose regimens at 1.6 to 16 mg over five to seven days, with 1.6 mg subcutaneous twice weekly the standard chronic hepatitis protocol [4]. Sepsis trials used 1.6 mg every 12 hours [2][3]. These are trial protocols, not personal instructions.
How does thymosin alpha 1 make you feel?
As an immune modulator, it does not produce a noticeable 'feeling' for most people. Community reports describe either nothing at all or a vague sense of resilience — both anecdotal, not clinical evidence [4]. The most commonly reported physical sensation is mild redness or stinging at the injection site, and occasionally a transient flu-like day.
How much thymosin alpha 1 should I take?
This site does not provide a human dose. The literature reports studied doses — single subcutaneous doses of 0.8 to 6.4 mg, and 1.6 mg twice weekly as the established hepatitis regimen — strictly as research data tied to specific supervised settings [4]. Extrapolating those to self-administration is unsupported. Any dosing decision belongs with a qualified clinician.
When is the best time to take thymosin alpha 1?
The literature does not establish an optimal time of day; trial protocols are defined by frequency and duration (for example, 1.6 mg twice weekly, or every 12 hours in sepsis studies) rather than clock timing [4][2]. Timing is therefore not something the evidence speaks to, and this digest offers no scheduling guidance for human use.
Is thymosin alpha 1 safe to take?
In studied clinical settings it is generally well tolerated; a comprehensive review and large post-marketing surveillance identify mild injection-site reactions, with occasional transient flu-like symptoms, as the dominant adverse events, and no documented organ toxicity at studied doses [4][17]. Separately, research-grade material is unregulated, so purity and identity are not guaranteed — a risk independent of the molecule itself [4].
Does thymosin alpha 1 help cancer?
It has been studied as an immunostimulatory adjuvant, not a standalone cancer treatment. A reappraisal positions it alongside chemo- and immunotherapy in melanoma, hepatocellular carcinoma, and lung cancer, potentially helping 'turn a cold tumour hot' and easing checkpoint-inhibitor toxicity [7]. The data are preclinical and clinical but heterogeneous; it is an adjunct under study, not an established therapy.
Is thymosin alpha 1 worth it?
That is a judgment this digest will not make for you, but the evidence picture matters: the strongest, most consistent signal is in chronic viral hepatitis, while the largest, most rigorous sepsis trial (TESTS, 1,106 adults) was null — no significant 28-day mortality benefit, hazard ratio 0.99 [3]. Benefits outside the best-studied settings should not be assumed.
Does thymosin affect aging?
Circulating Thymosin Alpha-1 levels decline with age, which is part of why vaccine-adjuvant research has explored it against immunosenescence (the age-related weakening of immunity) [1]. That is a rationale and a research direction, not proof of an anti-aging effect; no study in this digest establishes that the peptide slows aging itself.
Does thymosin alpha 1 reduce the mortality of severe COVID-19?
One retrospective review of 76 severe COVID-19 patients linked treatment to lower mortality (11.11% versus 30.00%, P=0.044) and to restored, less-exhausted T-cells [6]. But a 2022 systematic review of about 5,300 patients found no statistically significant overall mortality benefit. The honest answer: a promising retrospective signal that larger, controlled evidence has not confirmed.
Has anyone tried thymosin alpha 1 for chronic illness or immune issues?
Community members report using it for immune support and post-viral recovery, with mixed, anecdotal impressions and no controlled outcomes [4]. The formal record is sobering in places: in mouse models the peptide failed to improve lymphocyte immune reconstitution after stem-cell transfer, a notable negative for immune recovery [13]. Reported experience and proven benefit are not the same thing.
Thymosin alpha 1 vs thymosin beta 4 (TB-500) - what's the difference?
Thymosin Alpha-1 is a 28-amino-acid acetylated thymic peptide that modulates immunity via dendritic cells and T-cells [1]. Thymosin beta-4 (TB-500) is a 43-amino-acid actin-binding peptide involved in cell migration and tissue repair. Different sequence, size, mechanism, and use; they are not interchangeable, and thymosin beta-4 is the anti-doping-flagged one.